Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patient's tumor. DCVax product lines are made from the patient's own dendritic cells, which are freshly isolated, and matured and activated. The Company's DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.